Methylenetetrahydrofolate reductase gene polymorphisms:: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

被引：66

作者：

Marcuello, E

Altés, A

Menoyo, A

Del Rio, E

Baiget, M

机构：

[1] Hosp Santa Creu & Sant Pau, Dept Genet, Barcelona 08025, Spain

[2] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona 08025, Spain

[3] Hosp Esperit Sant, Dept Hematol, Barcelona 08923, Spain

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2006年 / 57卷 / 06期

关键词：

colon cancer; fluoropyrimidines; methylenetetrahydrofolate reductase; pharmacogenetics;

D O I：

10.1007/s00280-005-0089-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer. Methylenetetrahydrofolate reductase (MTHFR) may play a central role in the action of 5-FU, an inhibitor of thymidylate synthase, by converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. The aim of this study was to ascertain whether two polymorphisms in the MTHFR gene (677C > T and 1298 A > C) could be used as genomic predictors of clinical response to fluoropyrimidine-based chemotherapy (in combination with irinotecan or oxaliplatin). Ninety-four patients diagnosed with metastatic colorectal cancer and undergoing 5-FU-containing chemotherapy as a first line treatment were studied. The results suggest that the MTHFR genotype cannot be considered as an independent factor of outcome in colorectal cancer patients under 5-FU-based chemotherapy.

引用

收藏

页码：835 / 840

页数：6

相关论文

共 19 条

[1]

Cohen V, 2003, CLIN CANCER RES, V9, P1611

[2] THYMIDYLATE SYNTHETASE - TARGET ENZYME IN CANCER CHEMOTHERAPY [J].

DANENBERG, PV .

BIOCHIMICA ET BIOPHYSICA ACTA, 1977, 473 (02) :73-92

[3] Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity [J].

Etienne, MC ;

Ilc, K ;

Formento, JL ;

Laurent-Puig, P ;

Formento, P ;

Cheradame, S ;

Fischel, JL ;

Milano, G .

BRITISH JOURNAL OF CANCER, 2004, 90 (02) :526-534

[4] Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients [J].

Etienne, MC ;

Formento, JL ;

Chazal, M ;

Francoual, M ;

Magné, N ;

Formento, P ;

Bourgeon, A ;

Seitz, JF ;

Delpero, JR ;

Letoublon, C ;

Pezet, D ;

Milano, G .

PHARMACOGENETICS, 2004, 14 (12) :785-792

[5] A CANDIDATE GENETIC RISK FACTOR FOR VASCULAR-DISEASE - A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE [J].

FROSST, P ;

BLOM, HJ ;

MILOS, R ;

GOYETTE, P ;

SHEPPARD, CA ;

MATTHEWS, RG ;

BOERS, GJH ;

DENHEIJER, M ;

KLUIJTMANS, LAJ ;

VANDENHEUVEL, LP ;

ROZEN, R .

NATURE GENETICS, 1995, 10 (01) :111-113

[6] Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR) [J].

Goyette, P ;

Pai, A ;

Milos, R ;

Frosst, P ;

Tran, P ;

Chen, ZT ;

Chan, M ;

Rozen, R .

MAMMALIAN GENOME, 1998, 9 (08) :652-656

[7] Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity [J].

Jakobsen, A ;

Nielsen, JN ;

Gyldenkerne, N ;

Lindeberg, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1365-1369

[8] Genetic polymorphisms in the Hmong population - Implications for cancer etiology and survival [J].

Kiffmeyer, WR ;

Langer, E ;

Davies, SM ;

Envall, J ;

Robison, LL ;

Ross, JA .

CANCER, 2004, 100 (02) :411-417

[9] 5-Fluorouracil: Mechanisms of action and clinical strategies [J].

Longley, DB ;

Harkin, DP ;

Johnston, PG .

NATURE REVIEWS CANCER, 2003, 3 (05) :330-338

[10] Single nucleotide polymorphism in the 5′ tandem repeat sequences of Thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients [J].

Marcuello, E ;

Altés, A ;

del Rio, E ;

César, A ;

Menoyo, A ;

Baiget, M .

INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (05) :733-737